 Adam Dyson on Aug 17th, 2018 // No Comments
Fennec Pharmaceuticals Inc (NASDAQ:FENC) â€“ Research analysts at Wedbush cut their Q3 2018 earnings estimates for shares of Fennec Pharmaceuticals in a note issued to investors on Tuesday, August 14th. Wedbush analyst D. Nierengarten now expects that the company will post earnings per share of ($0.15) for the quarter, down from their prior estimate of ($0.11). Wedbush also issued estimates for Fennec Pharmaceuticals' Q4 2018 earnings at ($0.16) EPS, FY2018 earnings at ($0.54) EPS, Q1 2019 earnings at ($0.19) EPS, Q2 2019 earnings at ($0.20) EPS, Q4 2019 earnings at $3.44 EPS, FY2020 earnings at $0.36 EPS and FY2022 earnings at $2.59 EPS. Get Fennec Pharmaceuticals alerts:
Fennec Pharmaceuticals (NASDAQ:FENC) last announced its earnings results on Monday, August 13th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.04). Several other equities research analysts have also recently weighed in on the company. HC Wainwright set a $18.00 price objective on Fennec Pharmaceuticals and gave the company a "buy" rating in a research report on Tuesday, August 7th. Zacks Investment Research cut Fennec Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Wednesday. Finally, ValuEngine raised Fennec Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Thursday, May 17th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. The stock currently has a consensus rating of "Buy" and a consensus target price of $17.00.
Shares of Fennec Pharmaceuticals stock opened at $9.94 on Thursday. The company has a market cap of $188.13 million, a price-to-earnings ratio of -21.04 and a beta of -0.36. Fennec Pharmaceuticals has a 12-month low of $7.55 and a 12-month high of $14.99.
Several institutional investors and hedge funds have recently bought and sold shares of FENC. Creative Planning acquired a new position in shares of Fennec Pharmaceuticals in the second quarter valued at $105,000. Bronfman E.L. Rothschild L.P. acquired a new position in shares of Fennec Pharmaceuticals in the second quarter valued at $151,000. Schwab Charles Investment Management Inc. acquired a new position in shares of Fennec Pharmaceuticals in the second quarter valued at $221,000. Bank of New York Mellon Corp acquired a new position in shares of Fennec Pharmaceuticals in the second quarter valued at $237,000. Finally, Cardinal Capital Management raised its stake in shares of Fennec Pharmaceuticals by 116.4% in the second quarter. Cardinal Capital Management now owns 26,047 shares of the company's stock valued at $272,000 after purchasing an additional 14,010 shares in the last quarter. 40.85% of the stock is owned by institutional investors.
About Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children